Sapacitabine is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sapacitabine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sapacitabine is under development for the treatment of relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), breast cancer, ovarian cancer and pancreatic cancer. It is administered through oral route. Sapacitabine is pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine target DNA polymerase and acts through a dual mechanism, interfering with DNA synthesis. It is based on genomic technology. The drug candidate was also under development for the treatment of non-small cell lung cancer (NSCLC), cutaneous T cell lymphoma (CTCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Cyclacel Pharmaceuticals overview
Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. Cyclacel seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
For a complete picture of Sapacitabine’s drug-specific PTSR and LoA scores, buy the report here.